Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN FRANCISCO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported additional positive data from the Phase 1 clinical trial evaluating its second-g ...

Vaxart (NasdaqCM:VXRT) FY Conference September 08, 2025 12:00 PM ET Company ParticipantsSteven Lo - President, CEO & DirectorConference Call ParticipantsBrandon Folkes - MD & Senior Healthcare AnalystBrandon FolkesGood afternoon, everyone, and welcome to the HC Wainwright Annual Global Investment Conference. My name is Brandon Foulkes. I'm one of the Biopharma analysts here at HC Wainwright. Next up, we have a company presentation from Vaxart, and from Vaxart, we have CEO Stephen Lo. Stephen, over to you.St ...

会议延期安排 - 股东大会特别会议延期至2025年9月19日太平洋时间上午8:30举行 [1] - 延期原因包括董事会组成变更、额外治理改革考量及未来潜在披露事项 [1] - 会议以纯虚拟形式召开 需通过指定网址及16位控制码接入 [3] 投票相关事项 - 投票截止时间为2025年9月18日东部时间23:59 [1][5] - 股权登记日为2025年7月29日 [1][5] - 已提交的代理投票在未撤销情况下将继续有效 [4] - 反对反向拆股的股东可重新投票支持该提案 [5] 公司战略立场 - 管理层认为纳斯达克上市对推进科研及股东价值最大化至关重要 [2] - 反向拆股提案未在9月5日会议表决 旨在给予股东更充分考量时间 [2] - 公司将在未来两周持续与股东就上市议题进行沟通 [2] 企业业务概览 - 公司为临床阶段生物技术企业 专注口服重组疫苗研发 [6] - 核心技术为专利口服递送平台 具备无需冷藏及无针头接种优势 [6] - 研发管线涵盖冠状病毒、诺如病毒、流感口服疫苗及HPV治疗性疫苗 [6] - 已就腺病毒与TLR3激动剂口服接种技术申请国内外专利 [6] 联系信息 - 代理投票支持服务由Campaign Management公司提供 [5] - 投资者关系联系人为FINN Partners的Matt Steinberg [10]

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025. Presentation Details:Date and Time: Monday, September 8 at 12:00 PM ETWebcast: Click Here A live webcas ...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 202 ...

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M. Wallace, MD and David Whitney (collectively, the “Concerned Vaxart Stockholders”), who collectively beneficially own more than 2.5 million shares of Vaxart, Inc. (OTC: VXRT) (“Vaxart” or the “Company”) today urged fellow stockholders to vote “AGAINST” the Company’s proposed reverse stock split at the upcoming special meeting of stockholders ...

- Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline - SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it received a decision letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) on August 27, 2025, granting the Company’s ...

公司治理争议 - 一群合计持有超过250万股Vaxart股份的股东联合要求董事会问责并反对公司在2025年9月5日特别股东大会上提出的并股计划[1] - 在2025年年度股东大会上六名董事中有四名未能获得多数赞成票且股东强烈反对并股提案和高管薪酬议案但所有董事仍继续任职[2] - 董事会无视股东投票结果的行为模式对股东权利构成直接威胁并可能损害投资价值[3] 资本配置问题 - 公司在过去几年执行了三次相对于市价大幅折价的股权融资其中包括在2024年6月13日宣布获得非稀释性BARDA资助后立即进行的融资[3] - 董事会长期宣称寻求非稀释性融资但当真正获得非稀释性资金后却进行损害股东价值的融资操作凸显其行动与保护股东利益的承诺存在矛盾[4] 股东行动呼吁 - 股东团体敦促所有股东在特别股东大会上对并股计划投反对票以捍卫对革命性疫苗技术的投资并仔细考量董事会的过往记录[5]

公司动态 - 公司宣布高级管理团队将于2025年8月20日美国东部时间下午4:30/太平洋时间下午1:30参与虚拟股东炉边谈话 [1] - 炉边谈话将讨论反向股票分割的理由及恢复纳斯达克合规性的必要性 [2] - 公司鼓励截至2025年7月29日的记录股东在2025年9月4日美国东部时间晚上11:59前完成投票 [4] 股东沟通 - 股东可通过公司官网或指定链接观看炉边谈话直播 [2] - 投资者可在会议前通过ir@vaxartcom或网络直播门户提交书面问题 [3] - 活动结束后网络直播回放将在公司官网提供 [3] 代理顾问支持 - 领先的独立代理咨询公司ISS和Glass Lewis建议股东支持反向股票分割提案 [1][3] - 公司指定Campaign Management LLC为代理征集机构 提供投票协助服务 [4] 公司业务概述 - 公司为临床阶段生物技术企业 专注于基于专有递送平台的口服重组疫苗开发 [5] - 疫苗采用药丸形式 无需冷藏运输 避免针头注射风险 [5] - 研发管线包括针对冠状病毒 诺如病毒 流感的预防性疫苗 以及HPV治疗性疫苗 [5] - 已在全球提交多项专利 覆盖腺病毒和TLR3激动剂口服疫苗接种技术 [5]